ici 118551 has been researched along with verapamil in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Doggrell, SA | 1 |
| Denda, M; Fuziwara, S; Inoue, K | 1 |
3 other study(ies) available for ici 118551 and verapamil
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Assessment of the beta 2 adrenoceptor and Ca2+ channel-blocking activity of drugs with the rat portal vein.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Dobutamine; Isoproterenol; Male; Metoprolol; Muscle Contraction; Portal Vein; Propanolamines; Propranolol; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta; Verapamil | 1990 |
Beta2-adrenergic receptor antagonist accelerates skin barrier recovery and reduces epidermal hyperplasia induced by barrier disruption.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Biological Transport; Calcium; Calcium Channel Blockers; Calcium Channels; Clenbuterol; Epidermis; Humidity; Hyperplasia; Male; Mice; Mice, Hairless; Nifedipine; Procaterol; Propanolamines; Verapamil | 2003 |